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Diabetes poses a substantial burden to society as it can 
lead to serious complications and premature death. The 
number of cases continues to increase worldwide. Two 
major causes of diabetes are insulin resistance and insulin 
insufficiency. Currently, there are few antidiabetic drugs 
available that can preserve or protect β-cell function to 
overcome insulin insufficiency in diabetes. We describe 
a therapeutic strategy to preserve β-cell function by 
overexpression of follistatin (FST) using an AAV vector 
(AAV8-Ins-FST) in diabetic mouse model. Overexpres-
sion of FST in the pancreas of db/db mouse increased 
β-cell islet mass, decreased fasting glucose level, allevi-
ated diabetic symptoms, and essentially doubled lifes-
pan of the treated mice. The observed islet enlargement 
was attributed to β-cell proliferation as a result of bio-
neutralization of myostatin and activin by FST. Overall, 
our study indicates overexpression of FST in the diabetic 
pancreas preserves β-cell function by promoting β-cell 
proliferation, opening up a new therapeutic avenue for 
the treatment of diabetes.
Received 21 November 2014; accepted 4 February 2015; advance online 
publication 10 March 2015. doi:10.1038/mt.2015.29
INTRODUCTION
Diabetes is a chronic metabolic disorder characterized by hyper-
glycemia as a result of insulin deficiency and/or damaged tissue 
response to insulin.1,2 Traditional antidiabetic treatments mainly 
focus on glycemic control via administration of insulin or improv-
ing the tissue response to insulin.3,4 In fact, it is the β-cell deteriora-
tion that determines the rate and prognosis of the disease.5,6 Because 
there are few drugs available that can preserve or protect β-cells, 
any such therapy would revolutionize diabetes treatment. One of 
the most recent advancement in antidiabetic medication is the use 
of incretin-based therapies (i.e., glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors7,8). Glucagon-like 
peptide-1 receptor agonists increase insulin secretion in a glucose-
dependent manner, resulting in a low risk of hypoglycemia, and 
more importantly, offering a weight loss benefit when compared 
with insulin administration.9 Nevertheless, the glucagon-like pep-
tide-1 receptor agonists have limited effects in human β-cells.7,10
Follistatin (FST) emerges as a potential therapeutic candi-
date for preserving or protecting islet β-cell function. Originally 
recognized as an inhibitor of follicle-stimulating hormone, FST 
plays important roles in embryonic development, as well as in the 
proper functioning of the reproductive, endocrine, and muscu-
loskeletal systems.11–13 FST has earlier been used as an effective 
treatment for muscle degenerative diseases by increasing muscle 
fiber sizes through binding and bioneutralization of transform-
ing growth factor (TGF)-β superfamily members.14,15 Although 
the role of FST in the musculoskeletal system is clearly defined, 
information regarding the specific involvement of FST in pancre-
atic development and β-cell function is scarce and contains some 
degree of contradiction.14,16,17
Although the general consensus is that FST and its binding 
partners play important roles in the adult pancreas, some ambigu-
ity remains because of its complicated binding ligands, different 
and overlapping ligand receptors, and a multitude of downstream 
effectors.18 For example, activin A is antagonized by FST, yet is 
important in pancreatic development and controlling insulin 
secretion.19,20 On the other hand, overexpression of FST may 
prove to be an effective treatment strategy for obesity and diabe-
tes, as mice deficient in SMAD3 (Sma- and Mad-related protein 
3, a critical mediator of the TGF-β signaling pathway) exhibited 
increased circulating insulin levels and consequently decreased 
levels of blood glucose.21 Nevertheless, no direct evidence of the 
function of FST on β-cell in the pancreas currently exists.
In this study, we sought to investigate whether overexpres-
sion of FST in the pancreas preserves β-cell function in type 2 
diabetic mouse models. The mouse FST gene was driven by insu-
lin promoter to achieve β-cell specific transgene expression, and 
the adeno-associated virus serotype 8 (AAV8) vector was used to 
obtain robust transgene expression in the pancreas.22 Our results 
showed that long-term overexpression of FST in the pancreas of 
db/db mice promoted β-cell proliferation and maintained pancre-
atic islet mass. db/db mouse is a leptin receptor deficient type 2 
diabetes model. The function of leptin hormone is to regulate hun-
ger and energy expenditure by acting on its receptor in the hypo-
thalamus and peripheral targets. The absence of leptin receptor in 
the db/db mice leads to metabolic syndrome with severe obesity 
and type 2 diabetes.23 The treatment also ameliorated hyperglyce-
mia, relieved diabetic symptoms, and prolonged life span of the 
diabetic db/db mice despite the presence of obesity. We found that 
FST treatment inhibited SMAD2/3 signaling and consequently 
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These results are consistent with our hypothesis that FST plays an 
important role in maintaining glucose homeostasis by promoting 
β-cell proliferation in diabetic mice. Thus, overexpression of FST 
represents a novel therapeutic strategy for type 2 diabetes.
RESULTS
AAV8-Ins-FST delivery ameliorates diabetic symptoms 
and extends lifespan of db/db mice
To evaluate the function of FST in the islets of diabetic mice, 
the AAV8-Ins-FST vector (5 × 1011 vg/mouse) was delivered into 
6-week-old db/db mice (n = 5) via intraperitoneal injection. Our 
earlier study indicated that intraperitoneal. injection of AAV8 
vector driven by an insulin promoter rendered strong and highly 
specific gene expression in ββ-cells.24 FST expression in the pan-
creas was determined by both real-time PCR and immunofluo-
rescent (IF) staining. FST expression in the pancreas is naturally 
low in the wild-type C57BL/6 mouse.25 FST mRNA is even lower 
in the pancreas of db/db mice (0.16 ± 0.08) when compared with 
that of the wild-type mice. AAV8-Ins-FST treatment resulted in a 
significant increase of FST mRNA (Figure 1a). The relatively low 
follistatin expression revealed by IF staining (Figure 2a, green) 
was mainly due to the secretable nature of the protein and relative 
long period of time post vector delivery (the mice were sacrificed 
at 8.5 months of age). Because diabetes is characterized by hyper-
glycemia, polyuria, polydipsia, and sometimes polyphagia, we 
monitored blood glucose, water, and food intake in both treated 
and untreated mice. Blood glucose in treated mice began to drop 
significantly as early as 2 weeks after treatment (292 ± 70.46 mg/dl 
in treated group versus 403 ± 41.03 mg/dl in control group, n = 5, 
p = 0.008), and reached to 155 ± 35 mg/dl in treated group at ~1 year 
after treatment (Figure 1d). Meanwhile, water intake (Figure 1e) 
and food intake (Figure 1f) were also significantly reduced in 
treated mice (109.73 ± 1.5 g/kg/day for food, 12.2 ± 1.5 ml/day for 
water, n = 5) when compared with their untreated counterparts 
(151.81 ± 3.9 g/kg/day for food, n = 4, P = 0.00003, 19.73 ± 1.22 ml/
day for water, n = 3, p = 0.009) at 20 weeks after treatment.
We also investigated the effects of overexpression of FST on 
severe diabetes by delivering the vector into 5-month-old db/db 
mice, which showed very severe hyperglycemia and also started 
to have diminished insulin production. This therapeutic regi-
men resembles current clinical practice whereby treatment is 
given after the disease manifestation. The AAV8-Ins-FST vector 
(5 × 1011 vg/mouse) was administered intraperitoneally. to the 
5-month-old db/db mice (n = 4) and the age-matched untreated 
db/db mice were used as controls. The onset of the therapeu-
tic effect of FST appeared delayed in the aged group compared 
to the younger-treated group mentioned earlier. At 11 months 
post-treatment, blood glucose levels of the treated group steadily 
dropped to 145.5 ± 56 mg/dl; however, none of the control db/db 
mice survived past 5 months after treatment (Figure 1g). Similar 
to the phenomenon observed in the younger-treated group, water 
and food intake were also significantly decreased by the treatment 
(Figure 1h, i). Overall, these results suggest that overexpression 
of FST in pancreatic β-cells can alleviate glucose homeostasis 
impairment and ameliorate diabetic symptoms in db/db mice.
Finally, the important characteristic of db/db mice is their 
short life span. The average life span of the untreated db/db mice 
was 242.4 ± 80.79 days (n = 19), whereas the average life span 
of the treated db/db mice was almost doubled to 427.56 ± 44.95 
days (n = 9, p < 0.0001) (Figure 1b), although their body weights 
were even greater than the untreated db/db mice (Figure 1c). 
The metabolism was slower in the treated db/db mice when com-
pared with the that of the untreated counterpart (Supplementary 
Figure S2). This data clearly indicates that overexpression of FST 
improves survival of db/db mice despite the presence of obesity.
Because insulin deficiency is a key culprit in diabetes progres-
sion, we examined the impact of our treatment on serum levels 
of insulin. Similar to type 2 diabetes patients, the untreated db/
db mice were hyperinsulinemic during the early stages of the dis-
ease. Insulin serum levels of the db/db control mice at 3 months 
of age was higher than normal C57BL/6 mice (5.98 ± 2.91 µg/l 
versus 1.04 ± 0.43 µg/l, respectively, P = 0.002), and serum insu-
lin levels of the db/db mice declined with age (Figure 3a). When 
the db/db mice reached the end stage of the disease, insulin levels 
decreased to 1.69 ± 0.61 µg/l at 8–9 months of age. On the other 
hand, the serum insulin level of treated db/db stayed high and did 
not decrease over time. Serum insulin level of the treated mice 
was (8.52 ± 4.69 µg/l) at 3 months of age and remained high at 
10.26 ± 0.71 µg/l at 14 months of age (Figure 3a). Insulin expres-
sion (β-cell cytoplasmic insulin) in the pancreas was confirmed by 
real-time PCR, IF staining and Western blot. The mRNA expres-
sion of insulin in the pancreas of treated db/db mice was increased 
by 27.7-fold when compared with that of control mice (Figure 3b). 
IF staining revealed more insulin-positive cells in the treated group 
(Figure 2a,b), whereas Western blot showed much stronger insu-
lin expression than the controls (Figure 3c). It should be noted 
that insulin synthesized and stored in the β-cells of treated db/
db mice was still lower than that of the wild-type C57/BL6 mice 
(Figure 3c), although their serum insulin levels were higher.
FST treatment increased islet size by promoting  
β-cells proliferation
Prevention of β-cell decline is a key issue in type 2 diabetes mel-
litus treatment.6,26 To elucidate the effect of our treatment in this 
context, we sacrificed experimental mice at 8.5 months (n = 3) and 
15 months of age (n = 2). We observed a substantial increase in islet 
size with treatment as compared to control db/db mice and normal 
C57BL/6 mice (3.3-fold over db/db, P = 0.001, n = 4; 1.8-fold over 
C57BL/6, P = 0.01, n = 4) (Figure 4a). Correspondingly, the ratio of 
islet to pancreas area was also significantly increased in treated mice 
(4-fold over db/db mice, P = 0.001; 1.8-fold over C57BL/6 mice, P = 
0.02, n = 4) (Figure 4b). We next examined whether the treatment 
could improve the composition of islet cell type. To analyze cellular 
composition, double IF staining was performed against antibodies 
of insulin (β-cell) and glucagon (α-cell) or somatostatin (δ-cell) on 
paraffin embedded tissues (Figure 2b). Quantification data for the 
control db/db mice shows a decreased β-cell mass (40.9 ± 5.54%, n = 
4, P = 0.004) (Figure 4c) and increased α-cell (33.4 ± 4.59%, n = 4, 
p = 0.0004) (Figure 4d) and δ-cell (25.7 ± 4.14%, n = 4, P = 0.002) 
(Figure 4e) mass when compared with normal C57BL/6 mice 
(61.7 ± 0.42%, 19.13 ± 2.19%, 13.18 ± 1.91% of β-, α-, and δ-cell ratios, 
respectively). Remarkably, the AAV8-Ins-FST treatment completely 
normalized the β-cell (63.28 ± 5 .65%) and δ-cell (11.53 ± 2.16%) 
percentage (Figure  4c,e). The α-cell mass (23.6 ± 2.12%, n = 4, 
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P = 0.07) was slightly increased in the pancreas of the treated db/
db mice compared with that of the C57BL/6 mice, but it was sig-
nificantly improved when compared with the untreated db/db mice 
(Figure 4d). Therefore, AAV8-Ins-FST treatment increased islet 
size, number of β-cells, and normalized the β-cell to total islet cell 
ratio.
Potential mechanisms pertaining to preserved β-cell function 
include increasing β-cell proliferation or preventing cell death. To 
determine the contribution of cell proliferation, we performed 
coIF staining for proliferation marker Ki67 and β-cell marker 
insulin. Ki67 is a nuclear protein that is strictly associated with cel-
lular proliferation.27 As shown in Figure 2c, there were more Ki67 
positive cells in islets of treated mice than that of the control db/db 
mice. The β-cell proliferation rate in treated mice averaged about 
10-fold higher than in the control db/db mice (5.67 ± 1.72% ver-
sus 0.53 ± 0.45%, n = 3, P = 0.02) (Figure 4f). Costaining against 
Ki67 and glucagon (α-cell marker) in pancreas samples revealed 
that Ki67 positive cells were not glucagon-positive in both groups 
(Figure 2d), indicating that the proliferating cells were β-cells 
rather than α-cells in the treated islets. Notably, a few cells were 
positive for both insulin (red) and glucagon (green) (Figure 2e) 
in treated mice. These bihormonal cells (yellow) may either be 
undefined precursors that started to produce two hormones or 
pre-existing α-cells that started producing insulin, or both.28
Figure 1  Delivering AAV8-Ins-FST into pancreatic β-cells alleviated diabetic symptoms and prolonged lifespan in both young and old db/db 
mice. (a) mRNA expression of FST in the pancreas of db/db control, treated mice, and wild-type at 8.5 months old. (b) The AAV8-Ins-FST treatment 
significantly improved longevity of the diabetic mice. (c) Body weight of the AAV8-Ins-FST treated mice was increased compared to the control group. 
(d) Blood–glucose levels were decreased after long-term treatment in young treated mice. Mice were fasted for 16 hours (fasting longer period to 
obtain reading from glucose meter of the control mice) prior to sample collection. (e) The young treated mice consistently drank less water than the 
untreated controls; n = 3 per group. (f) Food intake (measured by g/kg/day) was reduced in young treated mice; n = 4 per group. (g) Blood glucose 
level slowly but steadily decreased in the aged treatment group (treated at 5-month-old of age). The control group did not survive past 5 months 
post-treatment. (h) Aged db/db mice drank significantly less water after AAV8-Ins-FST treatment than the controls. (i) Food intake at older age was 
significantly less in the treated group than the control; n = 5 for all groups if not otherwise specified. *P < 0.05 and **P < 0.005 compared to db/db 
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Figure 2 Immunofluorescent staining of different markers in control and treated pancreas. Displayed are single or multiple pancreatic islets. 
Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Individual scale bar (50 μm) are labeled to show the magnification scale. 
(a) Costaining of insulin (red) and FST (green) in the pancreas. (b) Morphology examination and IF staining against insulin (red), glucagon (green), 
and somatostatin (green) in the pancreatic islets. (c) Costaining of cell proliferation marker Ki67 (green) and β-cell marker insulin (red). (d) Costaining 
of cell proliferation marker Ki67 (green) and α-cell marker glucagon (red). (e) Costaining of insulin (red) and glucagon (green) shows some bihor-
monal (producing both insulin and glucagon, as shown by arrow) cells in AAV8-Ins-FST-treated mice. Nuclei were stained with DAPI (blue). Bottom 
row is magnified from middle pictures (as indicated by box and white arrow head) to show further detail. (f) Immunofluorescence staining of 
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Figure 3 Delivering AAV8-Ins-FST into pancreatic β-cells improved serum insulin levels. (a) AAV8-Ins-FST treatment at 5–6-week-old mice 
improved serum insulin levels in db/db mice (n = 5 for each group). (b) Levels of insulin mRNA were measured by RT-PCR and found to have increased 
27.7-fold in the treated pancreas as compared to the untreated pancreas (P = 0.0067, n = 5). Samples were taken from mice sacrificed at 8.5 months 
old. (c) Western blot analysis showed increased insulin expression in the treated islets compared to islets from untreated db/db mice. Insulin expres-
sion in wild-type C57BL/6 mice was greater than in the treated db/db mice (n = 3 for each group). The samples were from pooled islets of three mice. 
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Inhibition of SMAD pathway and activation of the 
PI3K-Akt pathway
To understand the molecular mechanisms underlying the β-cell 
proliferation observed following FST treatment, Western blot 
and IF staining were performed to detect relevant signaling path-
ways. In particular, the TGF-β-SMAD (Sma and Mad-related 
proteins) and the insulin-PI3K-Akt pathways were investigated. 
TGF-β superfamily ligands function through binding to cell sur-
face complexes, and different types of ligands trigger phosphor-
ylation of distinct receptor-mediated SMADs.29,30 The TGF-β 
ligands activin, myostatin, and nodal induce phosphorylation of 
SMAD2/3, whereas bone morphogenetic proteins (BMPs) ligand 
binding will result in phosphorylation of SMAD1/5/8.31 The level 
of phosphorylated SMAD2/3 (p-SMAD2/3) and SMAD1/5/8 
(p-SMAD1/5/8) in the treated versus untreated pancreas were 
revealed by IF staining. Both p-SMAD2/3 and p-SMAD1/5/8 
were significantly upregulated in the db/db pancreas as compared 
to the normal C57BL/6 pancreas (Figure 2f, Supplementary 
Figure S1). AAV8-Ins-FST treatment significantly inhibited 
SMAD2/3 signaling (76.3 ± 1.5% of p-SMAD2/3 cells in the 
treated db/db islets versus 95.3 ± 0.78% in untreated db/db islets, 
P = 0.0002, n = 3) (Figure 5a) and had less nuclear localization 
of p-SMAD2/3(Figure 2f), whereas SMAD1/5/8 signaling was 
slightly altered (66.1 ± 3.9% of p-SMAD1/5/8 cells in the treated 
db/db islets versus 76.7 ± 4.9% in untreated db/db islets, P > 0.05, n 
= 3) (Figure 5b and Supplementary Figure S1). This indicates the 
therapeutic effects of FST on islets are mainly through inhibition of 
SMAD2/3 pathway via bioneutralizaiton of myostatin, activin, or 
nodal. It is unclear whether SMAD1/5/8 pathway was also inhib-
ited in our study.
The PI3K-Akt pathway plays a critical role in the regulation of 
β-cell mass in the pancreas and defects in this signaling pathway 
have been shown to contribute to type 2 diabetes.32 To reveal the 
effect of FST treatment on this pathway, the pancreatic islets were 
isolated, pooled, and subjected to Western blot. Phosphorylated 
PI3K (p-PI3K) in the FST-treated pancreatic islets was greater than 
the untreated db/db islets (Figure 5c). Similarly, the total AKT and 
phosphorylated AKT (p-Akt) were both higher in islets isolated 
from FST-treated db/db mice compared with the untreated con-
trols (Figure 5c,d). Collectively, these results indicate that FST 
overexpression activates the insulin-PI3K-Akt signaling pathway.
Potential binding ligands of FST in the treated 
pancreas
To identify the targeting ligand(s) of FST in the treated pancreas, 
real-time PCR and real-time PCR array of the murine TGF-β/
BMP signaling pathway were performed on pancreatic cDNA 
from treated and control mice. Myostatin mRNA was significantly 
upregulated in the AAV8-Ins-FST-treated pancreas (Figure 6a). It 
is well known that myostatin gene expression is auto-regulated by 
a negative feedback mechanism.33 Therefore, the observed increase 
of myostatin mRNA in the treated pancreas indicates myostatin 
inhibition. In a similar fashion, activin (inhibin βA) mRNA was 
significantly upregulated in the treated pancreas (Figure 6a). 
In addition, we also noticed the mRNAs of two activin antago-
nists, BAMBI (BMP and activin membrane-bound inhibitor) 
Figure 4 Overexpression of follistatin (FST) in pancreatic β-cells increased islet numbers and mass, and normalized composition of islet cell 
types in db/db mice. (a) Mean islet size in the pancreas. Islet area was calculated using H&E images (10×) and positively-labeled pixels were quanti-
fied with Adobe Photoshop 7.0 software (n = 4 for each group). All islets were imaged. (b) The ratio of islet to total pancreas area was significantly 
increased in the AAV8-Ins-FST treated pancreas (n = 4 for each group). (c) Delivering AAV8-Ins-FST into the pancreas of db/db mice normalized the 
β-cell to total islet cell ratio. For each mouse, about 10,000 β-cells were counted, and there were four mice in each group. (d) α-cell to total islet cell 
ratio was decreased in the treated db/db mice as compared to the untreated db/db mice. (e) Treatment of AAV8-Ins-FST normalized δ-cell to total 
islet cell ratio in the pancreas of db/db mice. (f) Percentage of Ki67+ cells to insulin+ cells in the islets (n = 5 for AAV8-Ins-FST treated group, and n = 
4 for db/db control group). *P < 0.05 and **P < 0.005 compared to db/db control mice; #P < 0.05 and ##P < 0.005 compared to the C57BL/6 mice. 
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and inhibin-α, were upregulated (Figure 6a). BAMBI encodes a 
pseudo type I receptor, but lacks an intracellular kinase domain 
required for signaling, thereby functioning as a general negative 
regulator of TGF-β/BMP/activin signaling.34 Inhibin blocks the 
function of activin through competitive binding of both type I and 
type II receptors.35,36 Currently, it is unclear what mechanism drive 
the upregulation of BAMBI and inhibin-α mRNA expression in 
the FST-treated pancreas. The similar phenomenon, correlation 
of upregulation in BAMBI mRNA with a diminution in activin 
bioactivity, was observed at the time of gonocyte differentiation 
in germ cells.37 Nevertheless, the increase in mRNAs of myostatin, 
activin, and two activin inhibitors suggests blockade of myostatin 
and activin in the AAV8-Ins-FST treated pancreas.
Proliferation of pancreatic β-cell was responsible for the 
steady and persistent serum insulin level in the AAV8-Ins-FST 
treated db/db mice of our study. We next asked what factors might 
promote β-cell proliferation in this context. Of particular inter-
est, we noticed a significant increase of mitogenic factors betatro-
phin mRNA. Betatrophin is a newly identified hormone that 
promotes β-cell proliferation and improves glucose tolerance in 
mice.27 Betatrophin mRNA was significantly upregulated in the 
AAV8-Ins-FST treated pancreas (47.1 ± 17.17 fold, n = 3, P < 0.05) 
(Figure 6b). We hypothesized that betatrophin could be tran-
scriptionally repressed by activin, or myostatin, via SMAD3 path-
way; therefore, overexpression of FST in the β-cell would increase 
betatrophin expression and promote β-cell proliferation.
To further test our hypothesis, an in vitro reporter plasmid 
Beta-Luc was constructed in which a secretable gaussia lucif-
erase was driven by the betatrophin promoter (NCBI accession 
AC_000031, region 1910318–19105347). The Beta-Luc expres-
sion was evaluated in a mouse pancreatic β-cell line, NIT-1 cells. 
The Beta-Luc (Beta-Luc + pBSKS which is a control plasmid) 
elicited a significant amount of luciferase expression in the NIT-1 
cells, peaking at 2 days (48 hours) post-transfection. Activin-
conditioned media significantly inhibited luciferase expression 
to 26.8% (n = 3, P = 0.0008) at 48 hours (Figure 6c). Similarly, 
myostatin-conditioned media also inhibited luciferase expression 
(40.3%) at 48 hours, albeit to a less extent than the activin group 
(Figure 6c). As expected, FST plus activin or myostatin constructs 
partially recovered luciferase expression (50% for FST plus activin 
group versus 26.8% for activin alone, n = 3, P = 0.05 and 62.7% 
for FST plus myostatin group versus 40.3% for myostatin alone, 
Figure 5 Inhibition of SMAD pathway and activation of the PI3K-Akt 
pathway. (a) Percentage of phospho-SMAD2/3 nuclear positive cells 
to total islet cells. (b) Percentage of phospho-SMAD1/5/8 nuclear posi-
tive cells to total islet cells. (c) The expression of phosphorylated PI3K 
(p-PI3K), phosphorylation of Akt (p-Akt, ser473), and total Akt (t-Akt) in 
FST-treated islets was higher than the untreated db/db islets as shown 
by Western blot (n = 3 for each group). The samples for Western blot 
were from pooled islets of three mice. (d) Semiquantitative analysis of 
Western blot results for p-PI3K, p-Akt, and t-Akt *P < 0.05 compared 
to db/db control mice. #P < 0.05 compared to C57BL/6 mice. Data are 




























































































Figure 6 Promoting β-cell proliferation by inhibition of activin and myostatin via FST. (a) Relative mRNA expression of activin, myostatin, BAMBI, 
and inhibin-α by real-time PCR (or RT-PCR array) in the pancreas. (b) Relative mRNA expression of betatrophin in the pancreas by real-time PCR. (c) 
Inhibition of betatrophin expression by activin or myostatin shown using an in vitro reporter assay. NIT-1 cells were cotransfected with the mouse 
betatrophin promoter-luciferase plasmid (Beta-Gaussia-Luc), LacZ plasmid (transfection normalization control), and supplemented with conditional 
media for the indicated plasmids (refer to the section “Materials and Methods” for the details). pBSKS: bluescript control plasmid; ACT: activin plas-
mid driven by CB (Chick β-actin promoter with cytomegalovirus enhancer) promoter; FST: Follistatin plasmid driven by CAG promoter; Myo: myo-
statin plasmid driven by CB promoter. *P < 0.05 compared to untreated control; #P < 0.05 compared to pEMBOL-ds-CB-Activin; &P < 0.05 compared 
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n = 3, P = 0.01, Figure 6c). This in vitro reporter assay confirms 
our in vivo findings that overexpression of FST in the pancreas of 
diabetic mice increased mitogenic factor betatrophin expression 
by inhibition of activin and myostatin. This data also suggests that 
activin and myostatin can repress betatrophin transcription via 
acting on its promoter region in the pancreatic β-cells.
DISCUSSION
Diabetes is characterized by uncontrolled hyperglycemia and is 
linked to β-cell loss and dysfunction. Thus, preventing progressive 
loss of β-cell function is a key in treating diabetes. Here we describe 
a strategy to preserve and promote β-cell function via AAV-
mediated overexpression of FST in the pancreas. Administration 
of AAV8-Ins-FST into pancreatic β-cells in db/db mice improved 
mouse lifespan, reduced serum glucose level, and ameliorated 
diabetic symptoms. The most important finding of our study was 
that overexpression of FST increased islet size by promoting β-cell 
proliferation in db/db mice. We demonstrated that this occurred 
through inhibition of the SMAD2/3 signaling and subsequent 
activation of insulin-PI3K-Akt pathway via bioneutralization by 
FST with its ligands, mainly myostatin and activin in the treated 
pancreas. Most likely FST315 specifically expressed in the β-cells 
functions mainly as a local autocrine regulator. However, minor 
paracrine effects could not be ruled out because FST is a secretable 
protein. Our in vitro reporter assay further indicated that activin 
and myostatin could negatively regulate the transcription of mito-
genic factor betatrophin.27 Although we observed an upregula-
tion of betatrophin gene expression in the AAV FST-treated mice, 
the causative relationship between betatrophin expression and 
the observation of increased β-cell mass in our study remained 
unclear. Overexpression of FST in the pancreas of db/db mice 
might also increase some other mitogenic factors such as inhibi-
tors of DNA binding proteins ID2 (data not shown).38
Controversial findings exist, highlighting the importance 
of further investigation. One report was from a follistatin like-3 
(FSTL3) knockout study. FSTL3 and FST are structurally and 
functionally related glycoproteins that bind and antagonize actions 
of both activin and myostatin.39 Homozygous FSTL3 knockout 
mice displays increased pancreatic islet numbers and sizes, β-cell 
hyperplasia, and enhanced glucose tolerance.40 This phenom-
enon is quite different from what we have observed. Interestingly, 
FSTL3 knockout mice have opposite effects on glucose tolerance 
and insulin sensitivity compared to FST288-only mice, indicating 
FST and FSTL3 play different roles in regulating islet function and 
blood glucose homeostasis.41 FST is translated as three protein 
isoforms: the full length circulating isoform FST315, the tissue-
bound isoform FST288, and intermediate length gonad isoform 
FST303. They differ biochemically as well as in their distribution 
and mode of action. FST null mice are perinatally lethal; there-
fore, a mouse model that only expresses the tissue-bound FST288 
isoform was made and viable to evaluate the role of tissue-bound 
FST in regulating adult body composition and glucose homeo-
stasis.41 In agreement with our findings, islet-specific SMAD3 
knockout mice have increased insulin levels, decreased circulat-
ing glucose levels, and are protected from diet-induced obesity.42 
SMAD3 itself occupies the insulin gene promoter and represses 
insulin gene transcription.42 In addition, islet-specific SMAD3 
knockout mice have a more robust proliferative response after 
pancreatectomy.43
The conditional SMAD7 transgenic study is also worth men-
tioning.44 SMAD7 is an inhibitory SMAD which blocks TGF-β 
signaling by blocking all the receptor-mediated SMAD phosphor-
ylation and may also target TGF-β receptors for degradation.45 
SMAD7 expression in embryonic pancreas cells results in β-cell 
hypoplasia and neonatal lethality. These results actually do not 
contradict our findings, but emphasize the importance of bal-
anced SMAD signaling in β-cell development and maturation. 
Furthermore, SMAD signaling may play a different role in regulat-
ing β-cell proliferation in normal and diseased pancreas.46 SMAD 
inhibition may not be a strong stimulus for β-cell proliferation in 
a normal pancreas, where the signaling pathway is well balanced; 
however, it efficiently protects β-cell function in the diseased pan-
creas, where SMAD signaling is highly upregulated as revealed in 
our study.
The insulin-PI3K-Akt signaling pathway has been proven 
to play a critical role in the regulation of β-cell mass and func-
tion.32,47,48 Some evidence of this can be seen in the insulin receptor 
substrate 2 (Irs2, a key upstream regulator of the PI3K/Akt signal-
ing) knockout mice that show pathogenesis of type 2 diabetes as 
a consequence of combined insulin resistance and β-cell failure.49 
In addition, islets from type 2 diabetic patients exhibit reduced 
Irs2 expression, which supports the concept that altered Irs2-
dependent signaling leads to β-cell failure in human patients.50 In 
our study, FST treatment restored the PI3K-Akt pathway in the 
diabetic pancreas as seen by increased expression of p-P13K and 
Akt; therefore, the β-cell mass was increased, and diabetic symp-
toms were alleviated. However, the FST overexpression specifi-
cally in the pancreas, which we described in this study, was not 
sufficient to counteract peripheral insulin resistance. The treated 
db/db mice developed overt obesity in the end stage despite near-
normal glucose level and increased insulin secretion, as seen in 
nondiabetic obesity.51 On the other hand, systemic delivery of 
FST driven by ubiquitous promoter (which is out of scope of this 
manuscript) efficiently improved whole-body insulin sensitivity 
in addition to overcoming insulin insufficiency in the db/db mice. 
Future attempts of FST therapy may require ubiquitous expres-
sion of FST to overcome insulin insufficiency as well as insulin 
resistance.
Although we aimed to protect β-cell function via expressing 
therapeutic gene in pancreatic β-cells alone, we were surprised to 
find that FST treatment nearly doubled the lifespan of db/db mice. 
Our future direction will be to determine what factors attributed 
to this increased lifespan and how SMAD inhibition influences it. 
In summary, our study confirms that overexpression of FST in the 
pancreas can preserve β-cell function by promoting β-cell prolif-
eration, presenting a novel therapeutic strategy for type 2 diabetes.
MATERIALS AND METHODS
Plasmid construction and AAV vector production. The mouse FST cDNA 
was generated by a RT-PCR method from a mouse ovary tissue. The 
sequences of the primers used are: 5′-CAG GAT GGT CTG CGC CAG -3′ 
and 5′-GTT TTG CCC AAA GGC TAT GTC-3′. By restriction digest with 
enzymes NotI and SalI, the cDNA fragment was cohesively ligated to the 
AAV backbone vector pEMBOL containing the insulin promoter. The final 
construct was named pEMBOL-D(+)-Ins-FST. AAV serotype 8 was chosen 
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as our delivery vehicle to achieve robust β-cell transgene expression,22 and 
the final vector was named AAV8-Ins-FST. The AAV vector was produced by 
triple transfection method and the virus was purified by polyethylene glycol 
precipitation followed by CsCl centrifugation.52 The titer of AAV vector was 
determined by both dot-blot and real-time PCR methods. The concentration 
of viral vector stock was in the range of 2 × 1012–1 × 1013 vector genomes/ml.
Mice and vector administration. Male db/db (a rodent model of type 2 
diabetes) and C57BL/6 mice were purchased from the Jackson Laboratory 
at 4 weeks old. All animal protocols were approved by the University of 
North Carolina Animal Care and Use Committee. AAV8-Ins-FST vectors 
were delivered into the db/db mice at 6 weeks or 5 months old, by intraperi-
toneal injection at a final dose of 5 × 1011 vg/mouse.
Body weight, food, and water intake. Body weight was measured twice 
a month. Food intake and water intake were monitored for three times a 
week for 20 weeks after treatment.
Biochemical analysis. Blood glucose levels were measured using 
an ONETOUCH UltraSmart Blood Glucose Meter (LifeScan, New 
Brunswick, NJ, Cat # AW 060-795-01A). Blood was collected from the tail 
vein with a BD Microtainer Serum Seperator tube (REF 365956), and the 
serum was separated by spinning at 4 °C at 3000 RPM for 10 minutes in a 
micro centrifuge. Insulin concentrations were determined by ELISA using 
the Mercodia Mouse Insulin ELISA kit (Cat #10-1247-01).
Pancreas morphology and Immunohistochemistry. Pancreases were dis-
sected at the indicated age, fixed with 4% paraformaldehyde and embed-
ded in paraffin. H&E (hematoxylin and eosin) staining was performed 
on 5-µm paraffin sections using a previously reported method.53 For IF 
staining, paraffin sections were dewaxed by heating for 1 hour at 60ºC fol-
lowed by soaking in xylene three times for 5 minutes each. Sections were 
rehydrated two times each for 5 minutes in 100%, 95%, 80% ethanol, once 
for 5 minutes in 70% and 50% ethanol, and finally 5 minutes in H2O. They 
were then subjected to heat-mediated antigen retrieval (retrieval buffer: 
10 mmol/l sodium citrate, 0.05% Tween 20, pH 6.0). The sections were 
permeabilized with permeabilization buffer (0.2% Triton X-100 in PBS) 
for 45 minutes at room temperature. After blocking (10% horse serum 
in PBS), the sections were incubated with various primary antibodies 
overnight. The following primary antibodies were used: rabbit anti-FST 
antibody (Santa Cruz, Dallas, TX, Cat# sc-30194), guinea pig anti-insulin 
antibody (Abcam, Cambridge, UK, Cat# ab7842), mouse antiglucagon 
antibody (Sigma, St. Louis, MO, Cat# G2654), rabbit antisomatostatin 
antibody (Abcam, Cat#ab103790), rabbit anti-p-Smad2/3 antibody (Santa 
Cruz, Cat# sc-11769R), rabbit anti-p-Smad1/5/8 antibody, (Santa Cruz, 
Cat# sc-12353R), rabbit anti-Ki67 antibody (Dako, Carpinteria, CA, Cat# 
M7249). The ratios of insulin-positive β-cells, glucagon-positive α-cells, 
and somatostatin-positive δ-cells to total islet cells were calculated from 
40× images. All islets were imaged, and total β-cell number counted by 
counting nuclei surrounded by cytoplasmic insulin staining, total α-cell 
and δ-cell were counted in a similar method. For each mouse, about 10,000 
β-cells were counted, and the β-cell proliferation ratio was calculated by 
dividing Ki67+ cell number by the total β-cell number.
Islet isolation and Western blot. To isolate islets, we first clamped the 
ampulla with surgical thread on the duodenum wall to block the bile path-
way to the duodenum. Then, we injected 3 ml of Collagenase P enzyme 
(Sigma, C9263) at 0.5 mg/ml in a modified Hank’s balanced salt solution 
(Invitrogen, Carlsbad, CA) into the pancreas via the common bile duct to 
distend the pancreas. The pancreas was then excised whole and placed in 
modified Hank’s balanced salt solution for stationary digestion at 37 °C for 
15 minutes. Ficoll 400 (Sigma, Cat # F4375) was used at different densities 
to purify islets from acinar tissue.
Islets protein was extracted using lysis buffer (1% Triton X-100, 0.1% 
SDS, 0.25% sodium deoxycholate, 150 mmol/l Tris (pH 7.5), 150 mmol/l 
NaCl, 1 mmol/l EDTA) with phosphatase inhibitor (Sigma, Cat # P0044) 
and protease inhibitor (Sigma, Cat# P0044). Total protein was quantitated 
using a BCA kit (Pierce, Cat# 23227). Twenty micrograms of protein per 
lane and prestained molecular weight markers (Bio-Rad, Hercules, CA, 
Cat#161–0318) were separated with 12% SDS/PAGE gels and transferred 
to polyvinylidene fluoride membranes. Membranes were blocked at room 
temperature for 1 hour with blocking solution containing 5% nonfat 
dried milk in 10 mmol/l Tris–Cl (pH 7.5), 100 mmol/l NaCl, and 0.1% 
Tween-20 (TBS-T). Membranes were then incubated overnight at 4 °C 
with primary antibodies (rabbit anti-p-Akt (Ser473) Cell Signaling, 
Beverly, MA, Cat#9271), Akt (Cell Signaling, Cat#9272), p-PI3K p85 
(Cell Signaling, Cat#4228S) and GAPDH (Sigma, Cat#G9545), followed 
by secondary antibody incubation and developed with horseradish 
peroxidase-enhanced chemiluminescence.
Quantitative real-time PCR and real-time PCR array. Total RNA from 
the pancreas was extracted using TRIzol reagent (Invitrogen, Cat # 15596-
018). The cDNA was synthesized using Superscript III First Strand cDNA 
synthesis kit (Invitrogen, Cat# 18080-051). For quantitative real-time 
PCR, SYBR green-based method was used for individual targeted genes. 
Primer sequences are described in Supplementary Table S1. The GUSB 
(β-glucuronidase) (Applied Biosystems, Grand Island, NY, Mm00446953_
m1) was used as the endogenous control. The reaction was performed 
using the ABI 7300 real-time PCR system. The relative mRNA expression 
levels were calculated by the cycle threshold method (δ – δ Ct).
TGF-β/BMP signaling pathway PCR array was purchased from 
QIAGEN (TGFb BMP Signaling Pathway RT2 Profiler PCR Array, 
Cat. No: PAMM-035Z, Venlo, The Netherlands). The cDNA synthesis, 
PCR assembly, and data analysis were strictly followed according to the 
manufacturer’s protocol.
In vitro reporter assay. The mouse betatrophin promoter was cloned out 
with PCR method using a mouse liver sample. The primers used were 5′-
AGC TGA CGC GTG AAA TTG AGG CTG TGT GGG-3′ and 5′-TCA 
CGA CCT GCA GGA GGC AGA GAG CAA GCA C-3′. After restriction 
digest with enzymes PstI and SbfI, the cDNA fragment was cohesively ligated 
to the pxxLxp3.3 plasmid (originated in our lab) containing the cytomega-
lovirus promoter and secretable gaussia luciferase. The final construct was 
designated as pxxLxp3.3-Betatrophin-Luc (Beta-Luc). The NIT-1 cells were 
plated in 24-well plates 1 day before transfection. Each well was transfected 
with 0.7 µg of the reporter vector Beta-Luc and 0.7 µg pAAV2.1-CB-LacZ 
plasmid for normalization using AG Transgen Transfection Reagent (Cat# 
AGT002). Six hours after transfection, the transfection media was replaced 
with conditional media containing activin (ACT), FST, myostatin (Myo), 
ACT+FST, Myo+FST or control bluescript plasmid (pBSKS, 1/3 of the indi-
cated conditioned media + 0.5% FBS + 1 mmol/l sodium pyruvate). The 
media was harvested at different time points for Gaussia-Luc analysis. The 
activity of Gaussia-luc was determined using the BioLux Gaussia Luciferase 
Flex Assay Kit (BioLabs, Cat#E3308L) according to the manufacturer’s 
instructions. LacZ activity was measured using a classic colorimetric ortho-
nitrophenyl-β-galactoside (ONPG) assay method.54 Calculation of lucifer-
ase activity was normalized to LacZ activity. All assays were performed at 
least in triplicate.
Statistical analysis. Values are expressed as mean ± SEM. Welch’s t-test was 
applied when comparing two groups. When comparing three groups, one-
way analysis of variance (ANOVA) plus Dunnett post-test was applied using 
Graph Pad Prism software. P < 0.05 was considered statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. Immunofluorescence staining of phosphor-SMAD1/5/8 in 
the pancreas.
Figure S2. The metabolism was slower in AAV8-Ins-FST treated db/db 
mice measured by indirect gas calorimetry system (CaloSys).
Table S1. The oligonucleotide primer sequences for real-time PCR.
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